Study Links Gut Microbes to Coronary Artery Disease Risk

Cardiovascular diseases, responsible for nearly 20 million deaths annually, remain the leading cause of mortality globally. While genetics and environmental factors have been extensively studied, emerging research points to the significant role of gut microbes in the development of coronary artery disease (CAD). A recent study published in mSystems sheds light on how gut microbiota may influence CAD progression through various mechanisms.

Researchers from the Samsung Advanced Institute for Health Sciences and Technology at Sungkyunkwan University in Seoul conducted an investigation into the relationship between gut microbes and CAD. Led by genomicist Han-Na Kim, Ph.D., the study marks a shift from merely identifying gut bacteria to understanding their functional roles in the context of heart health.

The team analyzed fecal samples from 14 individuals with CAD in comparison to samples from 28 healthy participants. Utilizing metagenomic sequencing—a technique that reveals the entire DNA composition of a sample—the researchers successfully reconstructed the genomes of individual microbes. This approach allowed them to identify 15 bacterial species associated with CAD, along with pathways that link gut microbes to disease progression.

“Our high-resolution metagenomic map shows a dramatic functional shift toward inflammation and metabolic imbalance,” Dr. Kim noted. The study found a notable loss of protective bacteria, specifically short-chain fatty acid producers like Faecalibacterium prausnitzii, alongside an overactivation of pathways such as the urea cycle, which are linked to disease severity.

Interestingly, the genome-level analysis suggested that some beneficial bacteria can turn harmful depending on their environment. For instance, microbes traditionally viewed as healthy, such as Akkermansia muciniphila and F. prausnitzii, exhibit different functional roles in healthy versus diseased gut ecosystems.

The findings also highlighted the complexity of linking specific microbes to disease. Previous research has shown reduced levels of certain Lachnospiraceae species in CAD patients, while this study discovered elevated levels of others. Dr. Kim described these bacteria as potentially exhibiting a “Dr. Jekyll and Mr. Hyde” dynamic, where some strains could act as healers while others may contribute to disease progression. “The big unanswered question now is which strains are the healers, and which are the troublemakers,” she remarked.

Looking ahead, Dr. Kim emphasized the need to integrate microbial signals with genetic and metabolomic data to better map out causal pathways in heart disease. The overarching goal is to develop precision-based interventions that utilize microbial information to prevent cardiovascular diseases.

Dr. Kim stated that prevention remains the most promising strategy for mitigating the global burden of heart disease. By exploring microbial therapies, researchers hope to enhance stool-based screening methods or devise nutritional interventions that either restore beneficial bacteria or inhibit harmful pathways.

As this research unfolds, the potential implications for cardiovascular health and disease prevention could be substantial, offering new avenues for treatment and management strategies in the fight against heart disease.

More information can be found in the study published in mSystems in 2025.